Cargando…
Xenotransplantation: A New Era
Organ allotransplantation has now reached an impassable ceiling inherent to the limited supply of human donor organs. In the United States, there are currently over 100,000 individuals on the national transplant waiting list awaiting a kidney, heart, and/or liver transplant. This is in contrast with...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218200/ https://www.ncbi.nlm.nih.gov/pubmed/35757701 http://dx.doi.org/10.3389/fimmu.2022.900594 |
_version_ | 1784731829078589440 |
---|---|
author | Carrier, Amber N. Verma, Anjali Mohiuddin, Muhammad Pascual, Manuel Muller, Yannick D. Longchamp, Alban Bhati, Chandra Buhler, Leo H. Maluf, Daniel G. Meier, Raphael P. H. |
author_facet | Carrier, Amber N. Verma, Anjali Mohiuddin, Muhammad Pascual, Manuel Muller, Yannick D. Longchamp, Alban Bhati, Chandra Buhler, Leo H. Maluf, Daniel G. Meier, Raphael P. H. |
author_sort | Carrier, Amber N. |
collection | PubMed |
description | Organ allotransplantation has now reached an impassable ceiling inherent to the limited supply of human donor organs. In the United States, there are currently over 100,000 individuals on the national transplant waiting list awaiting a kidney, heart, and/or liver transplant. This is in contrast with only a fraction of them receiving a living or deceased donor allograft. Given the morbidity, mortality, costs, or absence of supportive treatments, xenotransplant has the potential to address the critical shortage in organ grafts. Last decade research efforts focused on creation of donor organs from pigs with various genes edited out using CRISPR technologies and utilizing non-human primates for trial. Three groups in the United States have recently moved forward with trials in human subjects and obtained initial successful results with pig-to-human heart and kidney xenotransplantation. This review serves as a brief discussion of the recent progress in xenotransplantation research, particularly as it concerns utilization of porcine heart, renal, and liver xenografts in clinical practice. |
format | Online Article Text |
id | pubmed-9218200 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92182002022-06-24 Xenotransplantation: A New Era Carrier, Amber N. Verma, Anjali Mohiuddin, Muhammad Pascual, Manuel Muller, Yannick D. Longchamp, Alban Bhati, Chandra Buhler, Leo H. Maluf, Daniel G. Meier, Raphael P. H. Front Immunol Immunology Organ allotransplantation has now reached an impassable ceiling inherent to the limited supply of human donor organs. In the United States, there are currently over 100,000 individuals on the national transplant waiting list awaiting a kidney, heart, and/or liver transplant. This is in contrast with only a fraction of them receiving a living or deceased donor allograft. Given the morbidity, mortality, costs, or absence of supportive treatments, xenotransplant has the potential to address the critical shortage in organ grafts. Last decade research efforts focused on creation of donor organs from pigs with various genes edited out using CRISPR technologies and utilizing non-human primates for trial. Three groups in the United States have recently moved forward with trials in human subjects and obtained initial successful results with pig-to-human heart and kidney xenotransplantation. This review serves as a brief discussion of the recent progress in xenotransplantation research, particularly as it concerns utilization of porcine heart, renal, and liver xenografts in clinical practice. Frontiers Media S.A. 2022-06-09 /pmc/articles/PMC9218200/ /pubmed/35757701 http://dx.doi.org/10.3389/fimmu.2022.900594 Text en Copyright © 2022 Carrier, Verma, Mohiuddin, Pascual, Muller, Longchamp, Bhati, Buhler, Maluf and Meier https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Carrier, Amber N. Verma, Anjali Mohiuddin, Muhammad Pascual, Manuel Muller, Yannick D. Longchamp, Alban Bhati, Chandra Buhler, Leo H. Maluf, Daniel G. Meier, Raphael P. H. Xenotransplantation: A New Era |
title | Xenotransplantation: A New Era |
title_full | Xenotransplantation: A New Era |
title_fullStr | Xenotransplantation: A New Era |
title_full_unstemmed | Xenotransplantation: A New Era |
title_short | Xenotransplantation: A New Era |
title_sort | xenotransplantation: a new era |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218200/ https://www.ncbi.nlm.nih.gov/pubmed/35757701 http://dx.doi.org/10.3389/fimmu.2022.900594 |
work_keys_str_mv | AT carrierambern xenotransplantationanewera AT vermaanjali xenotransplantationanewera AT mohiuddinmuhammad xenotransplantationanewera AT pascualmanuel xenotransplantationanewera AT mulleryannickd xenotransplantationanewera AT longchampalban xenotransplantationanewera AT bhatichandra xenotransplantationanewera AT buhlerleoh xenotransplantationanewera AT malufdanielg xenotransplantationanewera AT meierraphaelph xenotransplantationanewera |